Interim Report January - September 2007
KEY EVENTS DURING THE PERIOD- Net revenues amounted to MSEK 21.7 (80.3)- The loss after tax was MSEK 128.6 (loss: 20.5)- Earnings per share amounted to a loss of SEK 9.24 (loss: 1.54)- Orexo establishes a sales force in the Nordic markets by forming a joint venture with ProStrakan- The EU registration process of Rapinyl® has been referred to EMEA’s Committee for Medicinal Products for Human Use (CHMP)THIRD QUARTER 2007- Net revenues amounted to MSEK 6.5 (24.9)- The loss after tax was MSEK 34.1 (loss: 11.2)- Earnings per share amounted to a loss per share was SEK 2.44 (loss: